|

Case Study: Securing €7M in Equity Financing for a Biotech Scale-Up

Client Background

A biotech scale-up developing a groundbreaking therapeutic treatment was at a pivotal stage in its growth. The company needed €7M in equity financing to advance its clinical trials and obtain regulatory approval for market entry. Despite strong scientific validation, navigating the highly specialized investor landscape was a major challenge.

Challenge / Pain Points

  • High capital intensity: Clinical trials require significant funding, making investor selection crucial.
  • Regulatory complexity: Investors needed to understand the risks and milestones associated with the biotech approval process.
  • Specialized investor pool: The startup couldn’t rely on traditional venture capital alone—only biotech-focused investors with a long-term outlook would be a fit.
  • Fundraising inefficiency: The company had received mixed investor feedback in previous rounds and needed to sharpen its fundraising strategy.

Solution / Approach

1. Precision Investor Matching

  • TULA leveraged its extensive network to identify investors specializing in biotech, life sciences, and clinical-stage ventures.
  • We engaged both institutional biotech investors and family offices with a track record of investing in therapeutics.

2. Narrative & Pitch Optimization

  • We repositioned the investment story, emphasizing regulatory strategy, risk mitigation, and expected market impact.
  • The company’s pitch deck and financial model were refined to anticipate investor concerns about clinical trial timelines, capital efficiency, and market adoption.

3. Strategic Investor Outreach

  • We targeted investors with experience in late pre-clinical and Phase I/II trials, ensuring a higher success rate.
  • Our structured outreach process accelerated investor engagement and eliminated unproductive conversations, allowing the founders to focus on scientific milestones.

Outcome / Results

  • Secured €7M in equity funding from a consortium of biotech-specialized investors.
  • Strengthened investor confidence by addressing regulatory and clinical risk mitigation strategies upfront.
  • Accelerated the timeline for Phase II trials and positioned the company for a future Series B round.

Key Takeaways

  • Sector expertise is critical: A biotech scale-up needs investors who understand the capital cycles and risks of clinical trials.
  • Narrative matters: Framing regulatory and clinical risks strategically can make the difference between investor hesitation and commitment.
  • Efficient outreach saves time: Engaging the right investors from the outset prevents unnecessary delays in securing funding.

Raising capital for your biotech venture?

Partner with TULA for investor access, strategic positioning, and a streamlined fundraising process

Let’s grow